Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 19, 2015 9:31 AM ET


Company Overview of Adamas Pharmaceuticals, Inc.

Company Overview

Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company’s lead product candidate ADS-5102, which completed the Phase II/III clinical trial for the treatment of Parkinson's disease, known as levodopa induced dyskinesia. Its product portfolio also includes memantine-based therapeutics, which include Namenda XR, a treatment of moderate to severe dementia associated with Alzheimer's disease; and Namzaric, a once-daily fixed-dose combination of Namenda XR, which is being co-developed with Forest Laboratories, Inc. The company was f...

1900 Powell Street

Suite 750

Emeryville, CA 94608

United States

Founded in 2000

43 Employees





Key Executives for Adamas Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 50
Total Annual Compensation: $748.8K
Chief Operating Officer
Age: 48
Total Annual Compensation: $436.1K
Senior Vice President of Product Development
Age: 61
Total Annual Compensation: $503.0K
Compensation as of Fiscal Year 2014.

Adamas Pharmaceuticals, Inc. Key Developments

Adamas Pharmaceuticals, Inc. Receives Orphan Drug Designation for ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease

Adamas Pharmaceuticals, Inc. announced that the Food and Drug Administration has granted orphan drug status to ADS-5102 for the treatment of levodopa-induced dyskinesia associated with Parkinson's disease. Adamas currently has multiple Phase 3 studies underway evaluating ADS-5102 for this indication, which currently has no FDA-approved treatment options.

Adamas Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:00 AM

Adamas Pharmaceuticals, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 10:00 AM. Venue: Westin Grand Central Hotel, New York, New York, United States. Speakers: Gregory T. Went, Chairman and Chief Executive Officer.

Adamas Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

Adamas Pharmaceuticals, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenue of $55,846,000 compared to $71,095,000 a year ago. Income from operations was $18,514,000 compared to $57,018,000 a year ago. Income before income taxes was $17,597,000 compared to $52,112,000 a year ago. Net income attributable to common stockholders was $9,069,000 or $0.53 per diluted share compared to $35,353,000 or $3.00 per diluted share a year ago. Net cash provided by operating activities was $26,194,000 compared to $26,801,000 a year ago. Purchases of property and equipment was $1,285,000 compared to $167,000 a year ago.

Similar Private Companies By Industry

Company Name Region
Cytocentrics, Inc. United States
Molecular Imaging Products Company United States
Alvos Therapeutics, Inc. United States
Verichem Laboratories, Inc. United States
Advanced Glaucoma Technologies, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Adamas Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at